Team members

• Head of the platform: Stéphane De Botton, M.D.
• Lab manager: Cyril Quivoron, PhD (cyril.quivoron@gustaveroussy.fr)
• Marjorie Sabourin-Cousin, Technician
• Chaima Habib Allah, Technician

Activities

Reception and qualification of biological samples collected from patients with hematological malignancies treated at Gustave Roussy.  Translational research projects are addressed after validation by lab steering committee. Research projects are proposed by the Hematology Committee or DITEP members; contracts are validated by Gustave Roussy Transfert.

Real-Life Trials in Oncology Programme

Call for Applications 2023

A joint call between Gustave Roussy Foundation and CRIS Cancer Foundation. 

Gustave Roussy's medical-scientific programmes

Bioinformatics core facility - Major publications

• Nguyen-Khac, F. et al. Acquisition of TCF3 and CCND3 Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. Hemasphere 5, e563 (2021).
• Mazzi, S. et al. Dual role of EZH2 on megakaryocyte differentiation. Blood blood.2019004638 (2021) doi:10.1182/blood.2019004638.
• Kuksin, M. et al. Applications of single-cell and bulk RNA sequencing in onco-immunology. Eur J Cancer 149, 193–210 (2021).

Main publications

• Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselika L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021 Aug 17:S0923-7534(21)03978-8. doi: 10.1016/j.annonc.2021.08.1748. Epub ahead of print. PMID: 34416362.

Major publications

• Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Oulhen M, Pawlikowska P, Tayoun T, Garonzi M, Buson G, Forcato C, Manaresi N, Aberlenc A, Mezquita L, Lecluse Y, Lavaud P, Naltet C, Planchard D, Besse B, Farace F. NPJ Precis Oncol. 2021 Jul 16;5(1):67. doi: 10.1038/s41698-021-00203-1.PMID: 34272470

Team members

• Head of the platform
  Françoise Farace, PhD/HDR
  Email

• Engineer
  Patrycja Pawlikowska, PhD,

• Engineer
  Marianne Oulhen

• Technician
  Agathe Aberlenc

• PhD student
  Tala Tayoun

   

Equipment

• CellSearch platform for CTC and CEC enrichment and detection
• ISET filtration enrichment system for rare circulating cells (RareCells)
• Parsortix enrichment microfluidic system for CTCs (Angle) 
• VyCAP system for rare cell filtration 
• Automated filtration system Versant kPCR for rare cells (Siemens) 
• ARIOL scanner (LEICA microsystems) 
• ARIOL stations for microscopy image analysis (LEICA microsystems)
• Fluorescence microscope (Nikon)
• Laser microdissecteur (LEICA microsystems)

Activities

The platform is dedicated to the analysis of rare blood cell components such as circulating tumor cells (CTC) and circulating endothelial cells / progenitors (CEC / CEP), used as biomarkers in clinical trials.